Brief: Mirati Therapeutics Q2 product revenue USD 13.365 million
08/08/2023 21:59
Aug 8 (Reuters) - Mirati Therapeutics Q2 net income USD -176.913 million. * Q2 basic EPS USD -3.04 * Q2 operating expenses USD 200.96 million * Q2 operating income USD -187.27 million * Q2 product revenue USD 13.365 million
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)